103 Leveraging Digital Technology to Improve Breast Cancer Patients’ Understanding of Treatment Recommendations

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4

103 Leveraging Digital Technology to Improve Breast Cancer Patients’ Understanding of Treatment Recommendations

103 Leveraging Digital Technology to Improve Breast Cancer Patients’ Understanding of Treatment Recommendations

Background/Significance

Use of digital visual tools for communicating highly complex cancer treatment algorithms with patients may result in better understanding and improved patient experience. MyCareGorithm LLC developed a digital visual tool for communicating patient-specific explanations of treatments and procedures to cancer patients. The aim of this prospective pilot study is to assess the impact of digital visual tools on breast cancer patients understanding of their disease and treatment recommendations when used at the time of initial radiation oncology consultation.

Materials and Methods

In this IRB-approved study, we used the MyCareGorithm web based digital visual tools that provides an interactive digital interface incorporating breast cancer specific diagrams, animated visuals and videos on diagnosis and staging, treatment options and treatment recommendations including simulation procedures, treatment planning, and treatment delivery. MyCareGorithm LLC provided the tool at no cost for this pilot study.

Breast cancer patients and their companions willing to participate in a study evaluating this novel visual communication tool were enrolled. Forty English speaking breast cancer patients and 12 patient companions had an initial radiation oncology consultation with the MD/NP team. In addition to our standard verbal consultation format, we provided patients and their companions individualized disease-specific information using the digital visual tools. After consultation, patients and their companions completed a 6-question study survey. The survey responses are summarized to assess the impact of utilizing digital visual tools for radiation oncology consultation.

Results

The median age of this cohort is 57 years (range, 28-86). Race distribution is 15 White, 12 Black, and 13 Others. Survey responses from all (n = 40/40) breast cancer patients noted that their consultation experience was enhanced by using the MyCareGorithm digital visual tools. Almost all 97.5% (n = 39/40) patients noted that the visual images improved their ability to understand their medical situation and enhanced understanding of their treatment options. Seventy-seven percent (n = 31/40) of patients would look back and refer to digital visual tools information if available online, and 95% (n = 38/40) would recommend using this tool for other patients. On the survey, the 12 companions responded to all 6 questions in favor of using the digital visual tools.

Conclusion

Supplementing verbal communication at initial radiation oncology consultation with individualized digital visual content enhances the breast cancer patient’s consultation experience and improves understanding of the disease and complex treatments for both patients and their companions.

Articles in this issue

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)
TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)
90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective
90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective
91 Adverse Effects and Financial Burden of Radiation Therapy in Patients With T3N0M0 Luminal Breast Cancer
91 Adverse Effects and Financial Burden of Radiation Therapy in Patients With T3N0M0 Luminal Breast Cancer
92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer
92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer
96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States
96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States
97 Treatment Discontinuation Among Patients With Stage IV HER2–Negative Breast Cancer
97 Treatment Discontinuation Among Patients With Stage IV HER2–Negative Breast Cancer
TPS 99 Phase 3, Randomized, Open-Label TroFuse-010 Study of Sacituzumab Tirumotecan Alone and With Pembrolizumab Versus Treatment of Physician’s Choice Chemotherapy in Patients With HR+/HER2– Unresectable Locally Advanced or Metastatic Breast Cancer
TPS 99 Phase 3, Randomized, Open-Label TroFuse-010 Study of Sacituzumab Tirumotecan Alone and With Pembrolizumab Versus Treatment of Physician’s Choice Chemotherapy in Patients With HR+/HER2– Unresectable Locally Advanced or Metastatic Breast Cancer
100 Non-Pharmacological Interventions for Managing Abemaciclib-Associated Adverse Events in Patients With Early/Advanced HR+/HER2– Breast Cancer: A US-Based Health Care Provider Survey
100 Non-Pharmacological Interventions for Managing Abemaciclib-Associated Adverse Events in Patients With Early/Advanced HR+/HER2– Breast Cancer: A US-Based Health Care Provider Survey
102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer
102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer
103 Leveraging Digital Technology to Improve Breast Cancer Patients’ Understanding of Treatment Recommendations
103 Leveraging Digital Technology to Improve Breast Cancer Patients’ Understanding of Treatment Recommendations
104 Identification of Ductal Carcinoma In Situ Patients With Low-Risk Clinicopathology Who Benefit From Radiation Therapy With and Without Endocrine Therapy After Breast-Conserving Surgery Assessed With the 7-Gene Biosignature
104 Identification of Ductal Carcinoma In Situ Patients With Low-Risk Clinicopathology Who Benefit From Radiation Therapy With and Without Endocrine Therapy After Breast-Conserving Surgery Assessed With the 7-Gene Biosignature
TPS 105 ALISertib in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive, HER2-Negative Recurrent or Metastatic Breast Cancer: the Phase 2 ALISCA-Breast1 Study
TPS 105 ALISertib in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive, HER2-Negative Recurrent or Metastatic Breast Cancer: the Phase 2 ALISCA-Breast1 Study
106 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Interim Analysis of the Multinational, Prospective, Noninterventional Study ELEANOR (N=300)
106 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Interim Analysis of the Multinational, Prospective, Noninterventional Study ELEANOR (N=300)
107 Neratinib-Based Combination Treatments for Patients With HER2-Positive Breast Cancer Brain Metastases
107 Neratinib-Based Combination Treatments for Patients With HER2-Positive Breast Cancer Brain Metastases

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Related Content